glp-1 receptor agonists benefits Therapeutic of glucagon-like peptide-1 in GLP-1 receptor agonists | How

Description

Encouraging results: Novo Nordisks Wegovy, for example, has shown a 20% reduction in heart attack, stroke, or death from heart disease in recent trials

& Diamant, M

Statistically significant reduced incidence seen across multiple large cohorts For this analysis, the researchers looked at health records from 111,646 women ages 45 to 80 with a body mass index (BMI) of 25 or above (the overweight threshold) who had breast imaging and a documented outcome in the Penn Medicine EHR between January 2022 and June 2025

Retatrutide versus other weight management peptides Researchers frequently need to select between multiple compound options for their studies

Abbreviations ADA: American Diabetes Association CV: Cardiovascular CVOTs: Cardiovascular outcome trials GLP-1RA: Glucagon-like peptide-1 receptor agonists HR: Hazard ratios MACE: Major cardiovascular events SGLT-2i: Sodiumglucose transporter-2 inhibitors T2DM: Type 2 diabetes mellitus References Giugliano D, Maiorino MI, Longo M, Bellastella G, Chiodini P, Esposito K